Vaccinex, Inc. (VCNX): Price and Financial Metrics
GET POWR RATINGS... FREE!
VCNX Stock Summary
- VCNX's price/sales ratio is 508.36; that's higher than the P/S ratio of 99.11% of US stocks.
- With a year-over-year growth in debt of -52.03%, VACCINEX INC's debt growth rate surpasses just 5.09% of about US stocks.
- As for revenue growth, note that VCNX's revenue has grown -94.44% over the past 12 months; that beats the revenue growth of merely 1.08% of US companies in our set.
- Stocks that are quantitatively similar to VCNX, based on their financial statements, market capitalization, and price volatility, are DBVT, SONN, CANF, IPSC, and PULM.
- Visit VCNX's SEC page to see the company's official filings. To visit the company's web site, go to www.vaccinex.com.
VCNX Valuation Summary
- VCNX's price/sales ratio is 510; this is 24185.71% higher than that of the median Healthcare stock.
- VCNX's price/sales ratio has moved up 200.5 over the prior 54 months.
Below are key valuation metrics over time for VCNX.
VCNX's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- VCNX has a Quality Grade of D, ranking ahead of 11.88% of graded US stocks.
- VCNX's asset turnover comes in at 0.069 -- ranking 295th of 677 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows VCNX's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
VCNX Stock Price Chart Interactive Chart >
VCNX Price/Volume Stats
|Current price||$0.59||52-week high||$2.28|
|Prev. close||$0.59||52-week low||$0.41|
|Day high||$0.65||Avg. volume||51,250|
|50-day MA||$0.62||Dividend yield||N/A|
|200-day MA||$0.86||Market Cap||29.43M|
Vaccinex, Inc. (VCNX) Company Bio
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington’s disease. The company’s preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is based in Rochester, New York.
Most Popular Stories View All
VCNX Latest News Stream
|Loading, please wait...|
VCNX Latest Social Stream
View Full VCNX Social Stream
Latest VCNX News From Around the Web
Below are the latest news stories about VACCINEX INC that investors may wish to consider to help them evaluate VCNX as an investment opportunity.
In this article, we will be taking a look at the 13 best biotech penny stocks to buy now. To skip our detailed analysis of these stocks, you can go directly to see the 5 Best Biotech Penny Stocks To Buy Now. Biotechnology is a sector that has long been contributing to the improvement of […]
ROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, announced that on November 23, 2022, the company closed the private placement of an aggregate of 7,142,496 shares of its common stock at a purchase price of $0.5293 per share for aggregate gross proceeds of approximately $3.8 million. The private placement wa
Vaccinex ( NASDAQ:VCNX ) Third Quarter 2022 Results Key Financial Results Net loss: US$4.76m (loss narrowed by 8.6...
Continued Progress in Pepinemab Oncology and Neurology Clinical ProgramsPromising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patient enrollment continues in the Phase 1b/2 KEYNOTE B84 oncology and Phase 1/2a SIGNAL-AD Alzheimer’s studies Several posters and presentations expected at November Medical Meetings, the Society for Immunotherapy of Cancer (SITC 2022) and Huntington’s Study Group
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment OptionsROCHESTER, N.Y., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D), and its collaborators at Emory University and the Moffitt Cancer Center today announced that two abstracts, including an oral presen
VCNX Price Returns